BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aho VTE, Houser MC, Pereira PAB, Chang J, Rudi K, Paulin L, Hertzberg V, Auvinen P, Tansey MG, Scheperjans F. Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson's disease. Mol Neurodegener 2021;16:6. [PMID: 33557896 DOI: 10.1186/s13024-021-00427-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Lorente-Picón M, Laguna A. New Avenues for Parkinson's Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota. Biomolecules 2021;11:433. [PMID: 33804226 DOI: 10.3390/biom11030433] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Guo X, Tang P, Hou C, Chong L, Zhang X, Liu P, Chen L, Liu Y, Zhang L, Li R. Integrated Microbiome and Host Transcriptome Profiles Link Parkinson’s Disease to Blautia Genus: Evidence From Feces, Blood, and Brain. Front Microbiol 2022;13:875101. [DOI: 10.3389/fmicb.2022.875101] [Reference Citation Analysis]
3 Li Z, Lu G, Luo E, Wu B, Li Z, Guo J, Xia Z, Zheng C, Su Q, Zeng Y, Yee Chan W, Su X, Qiu X, Zheng X, Cai Q, Xu Y, Chen Y, Fan Y, Chen W, Yu Z, Chen X, Zheng C, Wang M, Sang Poon W, Luo X. Oral, Nasal, and Gut Microbiota in Parkinson's Disease. Neuroscience 2021:S0306-4522(21)00513-3. [PMID: 34695538 DOI: 10.1016/j.neuroscience.2021.10.011] [Reference Citation Analysis]
4 Mejía-granados DM, Villasana-salazar B, Coan AC, Rizzi L, Balthazar MLF, Godoi ABD, Canto AMD, Rosa DCD, Silva LS, Tacla RDR, Damasceno A, Donatti A, Avelar WM, Sousa A, Lopes-cendes I. Gut microbiome in neuropsychiatric disorders. Arq Neuro-Psiquiatr 2022;80:192-207. [DOI: 10.1590/0004-282x-anp-2021-0052] [Reference Citation Analysis]
5 Arikan M, Yildiz Z, Kahraman Demir T, Yilmaz NH, Sen A, Hanoglu L, Yildirim S. Axillary Microbiota Is Associated with Cognitive Impairment in Parkinson's Disease Patients. Microbiol Spectr 2022;:e0235821. [PMID: 35138147 DOI: 10.1128/spectrum.02358-21] [Reference Citation Analysis]
6 Shih MK, Tain YL, Cheng CM, Hsu CN, Chen YW, Huang HT, Chang CI, Hou CY. Separation and Identification of Resveratrol Butyrate Ester Complexes and Their Bioactivity in HepG2 Cell Models. Int J Mol Sci 2021;22:13539. [PMID: 34948341 DOI: 10.3390/ijms222413539] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Shannon KM. Gut-Derived Sterile Inflammation and Parkinson's Disease. Front Neurol 2022;13:831090. [DOI: 10.3389/fneur.2022.831090] [Reference Citation Analysis]
8 Ren B, Wang L, Mulati A, Liu Y, Liu Z, Liu X. Methionine Restriction Improves Gut Barrier Function by Reshaping Diurnal Rhythms of Inflammation-Related Microbes in Aged Mice. Front Nutr 2021;8:746592. [PMID: 35004799 DOI: 10.3389/fnut.2021.746592] [Reference Citation Analysis]
9 Anis E, Xie A, Brundin L, Brundin P. Digesting recent findings: gut alpha-synuclein, microbiome changes in Parkinson's disease. Trends Endocrinol Metab 2021:S1043-2760(21)00268-X. [PMID: 34949514 DOI: 10.1016/j.tem.2021.11.005] [Reference Citation Analysis]
10 Balaguer-Trias J, Deepika D, Schuhmacher M, Kumar V. Impact of Contaminants on Microbiota: Linking the Gut-Brain Axis with Neurotoxicity. Int J Environ Res Public Health 2022;19:1368. [PMID: 35162390 DOI: 10.3390/ijerph19031368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Park J, Kim CH. Regulation of common neurological disorders by gut microbial metabolites. Exp Mol Med 2021. [PMID: 34857900 DOI: 10.1038/s12276-021-00703-x] [Reference Citation Analysis]
12 Pereira PAB, Trivedi DK, Silverman J, Duru IC, Paulin L, Auvinen P, Scheperjans F. Multiomics implicate gut microbiota in altered lipid and energy metabolism in Parkinson's disease. NPJ Parkinsons Dis 2022;8:39. [PMID: 35411052 DOI: 10.1038/s41531-022-00300-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Cui C, Hong H, Shi Y, Zhou Y, Qiao CM, Zhao WJ, Zhao LP, Wu J, Quan W, Niu GY, Wu YB, Li CS, Cheng L, Hong Y, Shen YQ. Vancomycin Pretreatment on MPTP-Induced Parkinson's Disease Mice Exerts Neuroprotection by Suppressing Inflammation Both in Brain and Gut. J Neuroimmune Pharmacol 2022. [PMID: 35091889 DOI: 10.1007/s11481-021-10047-y] [Reference Citation Analysis]
14 Voigt RM, Wang Z, Brown JM, Engen PA, Naqib A, Goetz CG, Hall DA, Metman LV, Shaikh M, Forsyth CB, Keshavarzian A. Gut microbial metabolites in Parkinson's disease: Association with lifestyle, disease characteristics, and treatment status. Neurobiology of Disease 2022. [DOI: 10.1016/j.nbd.2022.105780] [Reference Citation Analysis]
15 Stopińska K, Radziwoń-Zaleska M, Domitrz I. The Microbiota-Gut-Brain Axis as a Key to Neuropsychiatric Disorders: A Mini Review. J Clin Med 2021;10:4640. [PMID: 34682763 DOI: 10.3390/jcm10204640] [Reference Citation Analysis]
16 das Neves SP, Delivanoglou N, Da Mesquita S. CNS-Draining Meningeal Lymphatic Vasculature: Roles, Conundrums and Future Challenges. Front Pharmacol 2021;12:655052. [PMID: 33995074 DOI: 10.3389/fphar.2021.655052] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Jackson A, Engen PA, Forsyth CB, Shaikh M, Naqib A, Wilber S, Frausto DM, Raeisi S, Green SJ, Bradaric BD, Persons AL, Voigt RM, Keshavarzian A. Intestinal Barrier Dysfunction in the Absence of Systemic Inflammation Fails to Exacerbate Motor Dysfunction and Brain Pathology in a Mouse Model of Parkinson's Disease. Front Neurol 2022;13:882628. [DOI: 10.3389/fneur.2022.882628] [Reference Citation Analysis]
18 Ratajczak W, Mizerski A, Rył A, Słojewski M, Sipak O, Piasecka M, Laszczyńska M. Alterations in fecal short chain fatty acids (SCFAs) and branched short-chain fatty acids (BCFAs) in men with benign prostatic hyperplasia (BPH) and metabolic syndrome (MetS). Aging (Albany NY) 2021;13:10934-54. [PMID: 33847600 DOI: 10.18632/aging.202968] [Reference Citation Analysis]
19 Shabbir U, Tyagi A, Elahi F, Aloo SO, Oh DH. The Potential Role of Polyphenols in Oxidative Stress and Inflammation Induced by Gut Microbiota in Alzheimer's Disease. Antioxidants (Basel) 2021;10:1370. [PMID: 34573002 DOI: 10.3390/antiox10091370] [Reference Citation Analysis]
20 Chen H, Wang K, Scheperjans F, Killinger B. Environmental triggers of Parkinson's disease - Implications of the Braak and dual-hit hypotheses. Neurobiol Dis 2021;163:105601. [PMID: 34954321 DOI: 10.1016/j.nbd.2021.105601] [Reference Citation Analysis]
21 Lubomski M, Xu X, Holmes AJ, Muller S, Yang JYH, Davis RL, Sue CM. The Gut Microbiome in Parkinson’s Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies. Front Aging Neurosci 2022;14:875261. [DOI: 10.3389/fnagi.2022.875261] [Reference Citation Analysis]
22 Padhi P, Worth C, Zenitsky G, Jin H, Sambamurti K, Anantharam V, Kanthasamy A, Kanthasamy AG. Mechanistic Insights Into Gut Microbiome Dysbiosis-Mediated Neuroimmune Dysregulation and Protein Misfolding and Clearance in the Pathogenesis of Chronic Neurodegenerative Disorders. Front Neurosci 2022;16:836605. [DOI: 10.3389/fnins.2022.836605] [Reference Citation Analysis]
23 Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol 2022. [PMID: 35246670 DOI: 10.1038/s41577-022-00684-6] [Reference Citation Analysis]
24 Sajdel-Sulkowska EM. Neuropsychiatric Ramifications of COVID-19: Short-Chain Fatty Acid Deficiency and Disturbance of Microbiota-Gut-Brain Axis Signaling. Biomed Res Int 2021;2021:7880448. [PMID: 34651049 DOI: 10.1155/2021/7880448] [Reference Citation Analysis]
25 Dadgostar E, Moghanlou M, Parvaresh M, Mohammadi S, Khandan M, Aschner M, Mirzaei H, Tamtaji OR. Can Berberine Serve as a New Therapy for Parkinson's Disease? Neurotox Res 2022. [PMID: 35666433 DOI: 10.1007/s12640-022-00526-2] [Reference Citation Analysis]
26 Lubomski M, Xu X, Holmes AJ, Muller S, Yang JYH, Davis RL, Sue CM. Nutritional Intake and Gut Microbiome Composition Predict Parkinson’s Disease. Front Aging Neurosci 2022;14:881872. [DOI: 10.3389/fnagi.2022.881872] [Reference Citation Analysis]
27 Yang X, Ai P, He X, Mo C, Zhang Y, Xu S, Lai Y, Qian Y, Xiao Q. Parkinson's Disease Is Associated with Impaired Gut-Blood Barrier for Short-Chain Fatty Acids. Mov Disord 2022. [PMID: 35607987 DOI: 10.1002/mds.29063] [Reference Citation Analysis]
28 Zhang H, Chen Y, Wang Z, Xie G, Liu M, Yuan B, Chai H, Wang W, Cheng P. Implications of Gut Microbiota in Neurodegenerative Diseases. Front Immunol 2022;13:785644. [DOI: 10.3389/fimmu.2022.785644] [Reference Citation Analysis]
29 Hang Z, Lei T, Zeng Z, Cai S, Bi W, Du H. Composition of intestinal flora affects the risk relationship between Alzheimer's disease/Parkinson's disease and cancer. Biomed Pharmacother 2022;145:112343. [PMID: 34864312 DOI: 10.1016/j.biopha.2021.112343] [Reference Citation Analysis]
30 Liao JX, Chen YW, Shih MK, Tain YL, Yeh YT, Chiu MH, Chang SKC, Hou CY. Resveratrol Butyrate Esters Inhibit BPA-Induced Liver Damage in Male Offspring Rats by Modulating Antioxidant Capacity and Gut Microbiota. Int J Mol Sci 2021;22:5273. [PMID: 34067838 DOI: 10.3390/ijms22105273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Chen SJ, Chen CC, Liao HY, Wu YW, Liou JM, Wu MS, Kuo CH, Lin CH. Alteration of Gut Microbial Metabolites in the Systemic Circulation of Patients with Parkinson's Disease. J Parkinsons Dis 2022;12:1219-30. [PMID: 35342048 DOI: 10.3233/JPD-223179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Brescia P, Rescigno M. The gut vascular barrier: a new player in the gut-liver-brain axis. Trends Mol Med 2021:S1471-4914(21)00154-4. [PMID: 34229973 DOI: 10.1016/j.molmed.2021.06.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Ren M, Natsagdorj N, Shun N. Influence and Mechanism of Polar Solvents on the Retention Time of Short-Chain Fatty Acids in Gas Chromatography. Separations 2022;9:124. [DOI: 10.3390/separations9050124] [Reference Citation Analysis]
34 Chen P, Zhang J, Wang C, Chai YH, Wu AG, Huang NY, Wang L. The pathogenesis and treatment mechanism of Parkinson's disease from the perspective of traditional Chinese medicine. Phytomedicine 2022;100:154044. [PMID: 35338993 DOI: 10.1016/j.phymed.2022.154044] [Reference Citation Analysis]
35 Li Y, Peng Y, Shen Y, Zhang Y, Liu L, Yang X. Dietary polyphenols: regulate the advanced glycation end products-RAGE axis and the microbiota-gut-brain axis to prevent neurodegenerative diseases. Crit Rev Food Sci Nutr 2022;:1-27. [PMID: 35587161 DOI: 10.1080/10408398.2022.2076064] [Reference Citation Analysis]
36 Fleming SM, Davis A, Simons E. Targeting alpha-synuclein via the immune system in Parkinson's disease: Current vaccine therapies. Neuropharmacology 2022;202:108870. [PMID: 34742741 DOI: 10.1016/j.neuropharm.2021.108870] [Reference Citation Analysis]